BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McKimm-Breschkin JL, Jiang S, Hui DS, Beigel JH, Govorkova EA, Lee N. Prevention and treatment of respiratory viral infections: Presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference. Antiviral Res 2018;149:118-42. [PMID: 29162476 DOI: 10.1016/j.antiviral.2017.11.013] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Ison MG, Scheetz MH. Understanding the pharmacokinetics of Favipiravir: Implications for treatment of influenza and COVID-19. EBioMedicine 2021;63:103204. [PMID: 33418497 DOI: 10.1016/j.ebiom.2020.103204] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
2 Wang Y, Ru Y, Zhuo G, Sheng M, Wang S, Ma J, Zhou C, Sun X, Zeng Y, Zhang Y, Li H, Lu Z, Wu D, Wu M. Investigation of the Potential Mechanism Governing the Effect of the Shen Zhu San on COVID-19 by Network Pharmacology. Evid Based Complement Alternat Med 2020;2020:8468303. [PMID: 33224256 DOI: 10.1155/2020/8468303] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Szabat M, Lorent D, Czapik T, Tomaszewska M, Kierzek E, Kierzek R. RNA Secondary Structure as a First Step for Rational Design of the Oligonucleotides towards Inhibition of Influenza A Virus Replication. Pathogens 2020;9:E925. [PMID: 33171815 DOI: 10.3390/pathogens9110925] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Yoshida I, Arikawa K, Honma Y, Inatani S, Yoshinaga M, Sugiyama H. Pharmacological Characterization of TP0591816, a Novel Macrocyclic Respiratory Syncytial Virus Fusion Inhibitor with Antiviral Activity against F Protein Mutants. Antimicrob Agents Chemother 2020;65:e01407-20. [PMID: 33046486 DOI: 10.1128/AAC.01407-20] [Reference Citation Analysis]
5 Nicholson EG, Munoz FM. A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children. Clin Ther 2018;40:1268-81. [PMID: 30077340 DOI: 10.1016/j.clinthera.2018.06.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
6 Sedeyn K, Saelens X. New antibody-based prevention and treatment options for influenza. Antiviral Res 2019;170:104562. [PMID: 31323236 DOI: 10.1016/j.antiviral.2019.104562] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
7 Pizzorno A, Padey B, Terrier O, Rosa-Calatrava M. Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy. Front Immunol 2019;10:531. [PMID: 30941148 DOI: 10.3389/fimmu.2019.00531] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 16.0] [Reference Citation Analysis]
8 Beigel JH, Hayden FG. Influenza Therapeutics in Clinical Practice-Challenges and Recent Advances. Cold Spring Harb Perspect Med 2021;11:a038463. [PMID: 32041763 DOI: 10.1101/cshperspect.a038463] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
9 Omoto S, Speranzini V, Hashimoto T, Noshi T, Yamaguchi H, Kawai M, Kawaguchi K, Uehara T, Shishido T, Naito A, Cusack S. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep 2018;8:9633. [PMID: 29941893 DOI: 10.1038/s41598-018-27890-4] [Cited by in Crossref: 169] [Cited by in F6Publishing: 159] [Article Influence: 42.3] [Reference Citation Analysis]
10 Bleibtreu A, Bertine M, Bertin C, Houhou-Fidouh N, Visseaux B. Focus on Middle East respiratory syndrome coronavirus (MERS-CoV). Med Mal Infect 2020;50:243-51. [PMID: 31727466 DOI: 10.1016/j.medmal.2019.10.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 8.7] [Reference Citation Analysis]
11 Beigel JH. Polyclonal and monoclonal antibodies for the treatment of influenza. Curr Opin Infect Dis 2018;31:527-34. [PMID: 30299360 DOI: 10.1097/QCO.0000000000000499] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
12 Mohl G, Liddle N, Nygaard J, Dorius A, Lyons N, Hodek J, Weber J, Michaelis DJ, Busath DD. Novel influenza inhibitors designed to target PB1 interactions with host importin RanBP5. Antiviral Res 2019;164:81-90. [PMID: 30742842 DOI: 10.1016/j.antiviral.2019.02.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Vos LM, Bruning AHL, Reitsma JB, Schuurman R, Riezebos-Brilman A, Hoepelman AIM, Oosterheert JJ. Rapid Molecular Tests for Influenza, Respiratory Syncytial Virus, and Other Respiratory Viruses: A Systematic Review of Diagnostic Accuracy and Clinical Impact Studies. Clin Infect Dis 2019;69:1243-53. [PMID: 30689772 DOI: 10.1093/cid/ciz056] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 21.5] [Reference Citation Analysis]
14 Alyami MH, Alyami HS, Warraich A. Middle East Respiratory Syndrome (MERS) and novel coronavirus disease-2019 (COVID-19): From causes to preventions in Saudi Arabia. Saudi Pharm J 2020;28:1481-91. [PMID: 32994704 DOI: 10.1016/j.jsps.2020.09.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
15 Bassetti M, Castaldo N, Carnelutti A. Neuraminidase inhibitors as a strategy for influenza treatment: pros, cons and future perspectives. Expert Opin Pharmacother 2019;20:1711-8. [PMID: 31169040 DOI: 10.1080/14656566.2019.1626824] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
16 Ison MG, Hayden FG, Hay AJ, Gubareva LV, Govorkova EA, Takashita E, McKimm-Breschkin JL. Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group. Antiviral Res 2021;194:105158. [PMID: 34363859 DOI: 10.1016/j.antiviral.2021.105158] [Reference Citation Analysis]
17 G Viveiros Rosa S, Fierro IM, C Santos W. Repositioning and investigational drugs for Zika virus infection treatment: a patent review. Expert Opin Ther Pat 2020;30:847-62. [PMID: 32842803 DOI: 10.1080/13543776.2020.1811854] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Rabaan AA, Al-Ahmed SH, Sah R, Alqumber MA, Haque S, Patel SK, Pathak M, Tiwari R, Yatoo MI, Haq AU, Bilal M, Dhama K, Rodriguez-Morales AJ. MERS-CoV: epidemiology, molecular dynamics, therapeutics, and future challenges. Ann Clin Microbiol Antimicrob 2021;20:8. [PMID: 33461573 DOI: 10.1186/s12941-020-00414-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
19 Twabela A, Okamatsu M, Matsuno K, Isoda N, Sakoda Y. Evaluation of Baloxavir Marboxil and Peramivir for the Treatment of High Pathogenicity Avian Influenza in Chickens. Viruses 2020;12:E1407. [PMID: 33302389 DOI: 10.3390/v12121407] [Reference Citation Analysis]
20 Potì F, Pozzoli C, Adami M, Poli E, Costa LG. Treatments for COVID-19: emerging drugs against the coronavirus. Acta Biomed 2020;91:118-36. [PMID: 32420936 DOI: 10.23750/abm.v91i2.9639] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
21 Lee N, Hurt AC. Neuraminidase inhibitor resistance in influenza: a clinical perspective. Curr Opin Infect Dis 2018;31:520-6. [PMID: 30299356 DOI: 10.1097/QCO.0000000000000498] [Cited by in Crossref: 41] [Cited by in F6Publishing: 18] [Article Influence: 13.7] [Reference Citation Analysis]
22 Zhou F, Wang Y, Liu Y, Liu X, Gu L, Zhang X, Pu Z, Yang G, Liu B, Nie Q, Xue B, Feng J, Guo Q, Liu J, Fan H, Chen J, Zhang Y, Xu Z, Pang M, Chen Y, Nie X, Cai Z, Xu J, Peng K, Li X, Xiang P, Zhang Z, Jiang S, Su X, Zhang J, Li Y, Jin X, Jiang R, Dong J, Song Y, Zhou H, Wang C, Cao B; CAP-China Network. Disease severity and clinical outcomes of community-acquired pneumonia caused by non-influenza respiratory viruses in adults: a multicentre prospective registry study from the CAP-China Network. Eur Respir J 2019;54:1802406. [PMID: 31164430 DOI: 10.1183/13993003.02406-2018] [Cited by in Crossref: 31] [Cited by in F6Publishing: 40] [Article Influence: 10.3] [Reference Citation Analysis]
23 Soto-Acosta R, Edwards TC, Dreis CD, Krishna VD, Cheeran MC, Qiu L, Xie J, Bonnac LF, Geraghty RJ. Enhancing the Antiviral Potency of Nucleobases for Potential Broad-Spectrum Antiviral Therapies. Viruses 2021;13:2508. [PMID: 34960780 DOI: 10.3390/v13122508] [Reference Citation Analysis]
24 Behzadi MA, Leyva-Grado VH. Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections. Front Microbiol 2019;10:1327. [PMID: 31275265 DOI: 10.3389/fmicb.2019.01327] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 15.7] [Reference Citation Analysis]
25 Wang Y, Fan G, Salam A, Horby P, Hayden FG, Chen C, Pan J, Zheng J, Lu B, Guo L, Wang C, Cao B. Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus Infection. J Infect Dis. 2020;221:1688-1698. [PMID: 31822885 DOI: 10.1093/infdis/jiz656] [Cited by in Crossref: 56] [Cited by in F6Publishing: 48] [Article Influence: 56.0] [Reference Citation Analysis]
26 Mifsud EJ, Hayden FG, Hurt AC. Antivirals targeting the polymerase complex of influenza viruses. Antiviral Res 2019;169:104545. [PMID: 31247246 DOI: 10.1016/j.antiviral.2019.104545] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 20.3] [Reference Citation Analysis]
27 Ianevski A, Zusinaite E, Kuivanen S, Strand M, Lysvand H, Teppor M, Kakkola L, Paavilainen H, Laajala M, Kallio-Kokko H, Valkonen M, Kantele A, Telling K, Lutsar I, Letjuka P, Metelitsa N, Oksenych V, Bjørås M, Nordbø SA, Dumpis U, Vitkauskiene A, Öhrmalm C, Bondeson K, Bergqvist A, Aittokallio T, Cox RJ, Evander M, Hukkanen V, Marjomaki V, Julkunen I, Vapalahti O, Tenson T, Merits A, Kainov D. Novel activities of safe-in-human broad-spectrum antiviral agents. Antiviral Res 2018;154:174-82. [PMID: 29698664 DOI: 10.1016/j.antiviral.2018.04.016] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 8.8] [Reference Citation Analysis]
28 Ashraf U, Tengo L, Le Corre L, Fournier G, Busca P, McCarthy AA, Rameix-Welti MA, Gravier-Pelletier C, Ruigrok RWH, Jacob Y, Vidalain PO, Pietrancosta N, Crépin T, Naffakh N. Destabilization of the human RED-SMU1 splicing complex as a basis for host-directed antiinfluenza strategy. Proc Natl Acad Sci U S A 2019;116:10968-77. [PMID: 31076555 DOI: 10.1073/pnas.1901214116] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Taniguchi K, Ando Y, Nobori H, Toba S, Noshi T, Kobayashi M, Kawai M, Yoshida R, Sato A, Shishido T, Naito A, Matsuno K, Okamatsu M, Sakoda Y, Kida H. Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil. Sci Rep 2019;9:3466. [PMID: 30837531 DOI: 10.1038/s41598-019-39683-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
30 Hayden FG, Shindo N. Influenza virus polymerase inhibitors in clinical development. Curr Opin Infect Dis 2019;32:176-86. [PMID: 30724789 DOI: 10.1097/QCO.0000000000000532] [Cited by in Crossref: 91] [Cited by in F6Publishing: 48] [Article Influence: 45.5] [Reference Citation Analysis]
31 Fusade-Boyer M, Dupré G, Bessière P, Khiar S, Quentin-Froignant C, Beck C, Lecollinet S, Rameix-Welti MA, Eléouët JF, Tangy F, Lajoie B, Bertagnoli S, Vidalain PO, Gallardo F, Volmer R. Evaluation of the Antiviral Activity of Sephin1 Treatment and Its Consequences on eIF2α Phosphorylation in Response to Viral Infections. Front Immunol 2019;10:134. [PMID: 30809223 DOI: 10.3389/fimmu.2019.00134] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
32 Spahr Y, Tschudin-Sutter S, Baettig V, Compagno F, Tamm M, Halter J, Gerull S, Passweg J, Hirsch HH, Khanna N. Community-Acquired Respiratory Paramyxovirus Infection After Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience. Open Forum Infect Dis 2018;5:ofy077. [PMID: 29780847 DOI: 10.1093/ofid/ofy077] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
33 Cai W, Wen H, Zhou Q, Wu L, Chen Y, Zhou H, Jin M. 14-Deoxy-11,12-didehydroandrographolide inhibits apoptosis in influenza A(H5N1) virus-infected human lung epithelial cells via the caspase-9-dependent intrinsic apoptotic pathway which contributes to its antiviral activity. Antiviral Res 2020;181:104885. [PMID: 32702348 DOI: 10.1016/j.antiviral.2020.104885] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
34 Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, Sims AC. Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference. Antiviral Res. 2019;167:45-67. [PMID: 30974127 DOI: 10.1016/j.antiviral.2019.04.006] [Cited by in Crossref: 79] [Cited by in F6Publishing: 67] [Article Influence: 26.3] [Reference Citation Analysis]
35 Muhialdin BJ, Zawawi N, Abdull Razis AF, Bakar J, Zarei M. Antiviral activity of fermented foods and their probiotics bacteria towards respiratory and alimentary tracts viruses. Food Control 2021;127:108140. [PMID: 33867696 DOI: 10.1016/j.foodcont.2021.108140] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
36 Letafati A, Najafi S, Mottahedi M, Karimzadeh M, Shahini A, Garousi S, Abbasi-Kolli M, Sadri Nahand J, Tamehri Zadeh SS, Hamblin MR, Rahimian N, Taghizadieh M, Mirzaei H. MicroRNA let-7 and viral infections: focus on mechanisms of action. Cell Mol Biol Lett 2022;27:14. [PMID: 35164678 DOI: 10.1186/s11658-022-00317-9] [Reference Citation Analysis]
37 El-Kafrawy SA, Sohrab SS, Mirza Z, Hassan AM, Alsaqaf F, Azhar EI. In Vitro Inhibitory Analysis of Rationally Designed siRNAs against MERS-CoV Replication in Huh7 Cells. Molecules 2021;26:2610. [PMID: 33947034 DOI: 10.3390/molecules26092610] [Reference Citation Analysis]
38 Laure M, Hamza H, Koch-Heier J, Quernheim M, Müller C, Schreiber A, Müller G, Pleschka S, Ludwig S, Planz O. Antiviral efficacy against influenza virus and pharmacokinetic analysis of a novel MEK-inhibitor, ATR-002, in cell culture and in the mouse model. Antiviral Res 2020;178:104806. [PMID: 32304723 DOI: 10.1016/j.antiviral.2020.104806] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
39 Mercorelli B, Palù G, Loregian A. Drug Repurposing for Viral Infectious Diseases: How Far Are We? Trends Microbiol 2018;26:865-76. [PMID: 29759926 DOI: 10.1016/j.tim.2018.04.004] [Cited by in Crossref: 104] [Cited by in F6Publishing: 103] [Article Influence: 26.0] [Reference Citation Analysis]
40 Lee N, Ison MG. Inhibiting Viral Polymerase and Neuraminidase in Treating Influenza. The Journal of Infectious Diseases 2019;219:1013-5. [DOI: 10.1093/infdis/jiy548] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
41 Masood N, Malik SS, Raja MN, Mubarik S, Yu C. Unraveling the Epidemiology, Geographical Distribution, and Genomic Evolution of Potentially Lethal Coronaviruses (SARS, MERS, and SARS CoV-2). Front Cell Infect Microbiol 2020;10:499. [PMID: 32974224 DOI: 10.3389/fcimb.2020.00499] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
42 Łagocka R, Dziedziejko V, Kłos P, Pawlik A. Favipiravir in Therapy of Viral Infections. J Clin Med 2021;10:E273. [PMID: 33451007 DOI: 10.3390/jcm10020273] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
43 Hay AJ, McCauley JW. The WHO global influenza surveillance and response system (GISRS)-A future perspective. Influenza Other Respir Viruses 2018;12:551-7. [PMID: 29722140 DOI: 10.1111/irv.12565] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
44 Ianevski A, Andersen PI, Merits A, Bjørås M, Kainov D. Expanding the activity spectrum of antiviral agents. Drug Discov Today 2019;24:1224-8. [PMID: 30980905 DOI: 10.1016/j.drudis.2019.04.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 6.3] [Reference Citation Analysis]
45 Wang Y, Zhong W, Salam A, Tarning J, Zhan Q, Huang JA, Weng H, Bai C, Ren Y, Yamada K, Wang D, Guo Q, Fang Q, Tsutomu S, Zou X, Li H, Gillesen A, Castle L, Chen C, Li H, Zhen J, Lu B, Duan J, Guo L, Jiang J, Cao R, Fan G, Li J, Hayden FG, Wang C, Horby P, Cao B. Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza. EBioMedicine 2020;62:103125. [PMID: 33232871 DOI: 10.1016/j.ebiom.2020.103125] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]